Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases Source: Eur Respir Rev, 27 (150) 180078; 10.1183/16000617.0078-2018 Year: 2018
Healthcare utilisation, cost and respiratory disease severity Source: Eur Respir J 2002; 20: Suppl. 38, 396s Year: 2002
Healthcare costs and resource use in patients with chronic obstructive pulmonary disease (COPD) in Ontario, Canada Source: Virtual Congress 2021 – Primary care organisation and epidemiology Year: 2021
Healthcare utilization and costs of pediatric home mechanical ventilation in Canada Source: International Congress 2019 – Epidemiology of childhood respiratory diseases Year: 2019
Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018
Healthcare utilization and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014
Health care system resource utilisation in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016
Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Management of chronic lung conditions Year: 2020
Healthcare utilisation in childhood interstitial lung diseases: Analysis of chILD-EU registry data Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease Year: 2016
Integrated care prevents hospitalisations for exacerbations in COPD patients Source: Eur Respir J 2006; 28: 123-130 Year: 2006
Benefits from a program for “early interstitial lung diseases” in primary care centers Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases Year: 2017
Persistent asthma: disease control, resource utilisation and direct costs Source: Eur Respir J 2002; 20: 260-267 Year: 2002
Association of COPD symptomatic burden with healthcare resource utilization and impairment on work and activity Source: International Congress 2016 – Asthma, COPD, and ACOS: physical activity, dietary aspects, and diseases burden Year: 2016
Interstitial lung diseases misdiagnosis: a Healthcare Improvement Science (HIS) approach Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment Year: 2018
Health care utilization and costs of asthma and COPD in the Netherlands Source: Eur Respir J 2005; 26: Suppl. 49, 383s Year: 2005
Profiling hospital performance to monitor the quality of care: the case of COPD Source: Eur Respir J 2010; 35: 1031-1038 Year: 2010
Diagnostic delay and misdiagnosis in interstitial lung disease(ILD) at primary health care level Source: International Congress 2016 – Managing multimorbidity and lifestyle change in primary care Year: 2016
Healthcare utilisation in chronic cough Source: Virtual Congress 2020 – Increase in health care utilisation of modern treatments compared with the increase in effectiveness Year: 2020
Assessment of general physicians’ knowledge in the public and private sectors about interstitial lung disease. Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017
Incidence and resource utilisation of pulmonary exacerbations in patients with cystic fibrosis in the UK Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010